Användning av cookies

Lunds universitet använder cookies för att se till att webbplatsen fungerar korrekt och för att förbättra din upplevelse.

Läs mer i vår cookiepolicy

Sökresultat

Filtrera

Nollställ filter

Filtyp

Din sökning på "*" gav 570681 sökträffar

No title

This paper proposes a new conceptual frame for the study of analogue video aesthetics in digital culture. Updating Guy Debord’s notion of a “society of the spectacle” (1994), it will argue that we have entered an age of retrospectacle whose dominant signifier is an aesthetics of "remanence"—a term that fuses the magnetic materiality of analogue video with the cultural situation in which it finds i

No title

A growing number of publications focuses on business in relation to degrowth. Such research, for example, considers what it would take for businesses to become degrowth-compatible, what business practices need to be in place, and how businesses would have to relate with nature, human and non-human beings. Although degrowth business scholarship has come a long way in the past couple of years, many

No title

Vem är den unge kamraten? Vad finns kvar av det som en gång var en rörelse? Vad hände med alla storslagna drömmar om att förändra världen? Vad gör vi om vi redan förlorat och våra fiender sitter vid makten? Med föreställningarna Våld & pedagogik och Kropp & straff ville dramatikern Henrik Bromander och regissören John Hanse skapa nya lärostycken som tog sikte på samtidens akuta frågor. Ins

No title

The free light chain (FLC) ratio is a critical part of risk stratification for monoclonal gammopathy of undetermined significance (MGUS). Recently, revised FLC reference intervals developed using the iStopMM cohort, accounting for age and renal function, have reduced the rate of abnormal findings. Here, we examine the implications of the revision in an independent Danish MGUS cohort. Of 6993 MGUS

No title

BACKGROUND: Lung cancer remains one of the most challenging diseases to treat due to its heterogeneity. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations are genetic drivers in numerous cancer types including lung adenocarcinoma (LUAD). Despite recent advances in KRAS-targeted therapies, treatment resistance and limited therapeutic options necessitate advanced preclinical models, such as